PROactive Evaluation of Function to Avoid CardioToxicity

Study summary

This study is intended to evaluate the ability of an intramyocardial strain analysis package with cardiac MRI to assist in the early detection and management of cardiotoxicity from therapeutics used to treat cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedMyoStrain®

The study team can explain what participation involves.

Who it may be forCardiotoxicity · Breast Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 29, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Washington University School of Medicine

Study sponsor

Study overview

What this study is about

Purpose: Supportive Care
Study type: Interventional
Phase: Phase 2
Sponsor: Washington University School of Medicine
Interventions being studied: Device: MyoStrain®

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Participant in the SURVIVE registry
Signed informed consent form for PROACT
Histological diagnosis of any cancer type (patients with treated and clinically stable brain metastasis are acceptable)
Scheduled to receive anti-cancer therapy (radiation therapy is permitted)

Reasons someone may not be able to joinExclusion criteria

Contraindication to magnetic resonance imaging (MRI)
Unable to comply with study investigations (in the judgment of the investigator)
Life expectancy less than 1 year
Note: If a patient develops a temporary contraindication (e.g. temporary tissue expanders in breast cancer patients) after the baseline MRI, follow up MRIs will be discontinued for safety for the duration in which the patient has the contraindication. However, once the patient is no longer contraindicated to receiving MRIs, the study schedule may resume with their next scheduled MRI time point from the date of enrollment. Therefore, some time points may be skipped during the patient's enrollment in the study. Also, if a patient needs a repeat MRI at any time point for any reason (i.e. panic attack during the MRI causing them to not be able to continue, unreadable images, etc.), we may repeat the MRI as long as the patient is willing.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Washington University School of MedicineSt Louis, Missouri

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 29, 2025. Always confirm current availability with the study team.

View original record ↗